论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zhang L, Ren Y, Wang Y, He Y, Feng W, Song C
Received 31 August 2017
Accepted for publication 3 January 2018
Published 26 February 2018 Volume 2018:13 Pages 1097—1105
DOI https://doi.org/10.2147/IJN.S150512
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Background: A
previous study developed a novel luteinizing hormone-releasing hormone (LHRH)
receptor-targeted liposome. The aim of this study was to further assess the
pharmacokinetics, biodistribution, and anti-tumor efficacy of LHRH
receptor-targeted liposomes loaded with the anticancer drug mitoxantrone
(MTO).
Methods: Plasma and tissue distribution profiles of LHRH receptor-targeted
MTO-loaded liposomes (LHRH-MTO-LIPs) were quantified in healthy mice or a
xenograft tumor nude mouse model of MCF-7 breast cancer, and were compared with
non-targeted liposomes and a free-drug solution.
Results: The LHRH-MTO-LIPs demonstrated a superior pharmacokinetic profile
relative to free MTO. The first target site of accumulation is the kidney,
followed by the liver, and then the tumor; maximal tumor accumulation occurs at
4 h post-administration. Moreover, the LHRH-MTO-LIPs exhibited enhanced
inhibition of MCF-7 breast cancer cell growth in vivo compared with
non-targeted MTO-loaded liposomes (MTO-LIPs) and free MTO.
Conclusion: The novel LHRH receptor-targeted liposome may become a viable
platform for the future targeted treatment of cancer.
Keywords: liposome, mitoxantrone, luteinizing hormone-releasing hormone
receptor, tumor targeting, gonadorelin